TrialHuman vaccines & immunotherapeutics2021

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial.

Sumantra Sarkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.